Prime Medicine (PRME) Earnings Analysis

Prime Medicine (PRME) next reports earnings on 2026-08-06, consensus EPS -0.24 USD. Last quarter (2026-05-07) it missed with EPS -0.28 USD vs -0.24 USD est (-16.7%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -2.44.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PRME next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.24 USD
Revenue estimate0.00B

PRME earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.28 USD-0.24 USD-16.7%Miss
2026-03-03-0.22 USD-0.25 USD+12%Beat
2025-11-07-0.32 USD-0.28 USD-14.3%Miss
2025-08-07-0.41 USD-0.36 USD-13.9%Miss
2025-02-28-0.31 USD-0.37 USD+16.2%Beat

Beat rate: 2/5 (40%) over reported quarters with consensus data.

PRME valuation and analyst view

Trailing P/E-2.44
Trailing EPS-1.12015 USD
Price / book7.13
Dividend yield0.00%
Market cap0.55B
Analyst consensusBuy (6 buy / 3 hold / 0 sell)
Avg price target7 USD

Related research pages

Frequently asked questions

When is Prime Medicine (PRME)'s next earnings date?

Prime Medicine is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.24 USD and revenue estimate of 0.00B.

Did PRME beat earnings last quarter?

In its 2026-05-07 report, PRME posted EPS of -0.28 USD versus a -0.24 USD estimate — a miss of 16.7%.

What is PRME's earnings track record?

Over the last 5 reported quarters with consensus data, PRME beat estimates 2 times (40%).

What is PRME's current P/E ratio and EPS?

PRME trades at a trailing P/E of -2.44 on trailing EPS of -1.1201481002771234 USD.

What do analysts rate PRME?

Analyst consensus is "Buy" across 9 ratings (0 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 7 USD.